Advanced cases of MDS require bone marrow transplantation. The average survival rate without a bone marrow transplant is about six years, but some patients can die within months from rapid bone marrow failure. Detecting a silent trigger Starczynowski and his colleagues have been studying MDS for y...
The 5-year relapse rate was 36%, 47% and 40%, respectively (P=0.17). MVA identified advanced disease as the major adverse factor, while FT had significantly lower relapse rate (hazard ratio 0.6, P=0.03). The 5-year survival (OS) was 37% with advanced disease. HCT-CI >2 and age ...
Allogeneic stem cell transplantation (ASCT) remains, when feasible, the only curative treatment option of higher-risk myelodysplastic syndrome (MDS) with prolonged disease-free survival observed in 35% to 50% of the patients. Based on the recommendation from an international expert panel, it is rec...
(d) Post-transplant red cell indices at the indicated time of recipient mice (4 1-year-old when transplanted) transplanted with bone marrow cells from old DWT or DKO mice (41-year-old). N = 10 in each group. (e) Kaplan–Meier survival analysis of the recipient mice in (d). N = ...
Allogeneic hematopoietic cell transplant (alloHCT) is theorized to be a curative therapeutic approach for patients with MDS. At 1 year, the OS rate and RFS rate are approximately 65% and 69% in patients with MDS who underwent myeloablative conditioning, as seen in the RIMAC study.2 However,...
Strikingly, the first prospective study focusing on MDS patients reported a trend of a better 2-year overall survival rate of 76.3% (95% CI, 65.8% to 86.9%) after RIC versus 63.2% (95% CI, 51.1% to 75.2%) after MAC (p = 0.08) according to univariate analysis; in the multivariate ...
3. DENNIS A E, INGRID B, INA M, et al. Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma:a systematic review and meta-analysis of randomized clinical ...
Overall, the hematologic response rate was 29.8%. Nearly half (47%) of the patients on the study died at the data cutoff. The median OS was 929 days (95% CI, 526-NE). The median leukemia- free survival was 690 days (95% CI, 428-934).15 Study authors selected 10-mg decitabine ...
10.1038/ncomms10004 Myelodysplastic syndromes (MDS) are clonal haemato- poietic disorders with diverse phenotypes, characterized by varying severity of ineffective haematopoiesis, bone marrow (BM) dysplasia, variable rates of progression to acute myeloid leukaemia (AML), overall survival and response to ...
What we are going to know, at least by the end of the year, is the CR rate in the first 190 patients. The trial is actively accruing up to over 500 patients with a secondary end point of overall survival. Hopefully, we are going to have both of thes...